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A 29-year-old German man of Caucasian origin 
presented with a 3-day history of headache, malaise 
and fever following a 4-week trip to The Gambia, West 
Africa. He did not receive any pre-travel vaccinations, 
and nor did he take malaria prophylaxis, but he remained 
well throughout his journey and for 1 week afterwards, 
until he fell acutely ill. Except for a moderately enlarged 
spleen (18 cm in diameter), his physical examination was 
unremarkab1e.A chest radiograph and an electrocardio- 
gram were normal. Laboratory tests on admission were 
normal except for moderate thrombocytopenia (7YnL) 
and low haptoglobin (28 mg/dL). Lactate dehydrogenase 
(LDH) (357 U/L), total bilirubin (1.1 mg/dL) and C- 
reactive protein (5.2 mg/dL) levels were slightly elevated. 
As suspected, microscopy of Giemsa-stained thick and 
thin blood films showed Plasmodium falciparum tropho- 
zoites at moderate density, with approximately 2% of 
erythrocytes infected. A lipid profile performed on a 
fasting blood sample during his stay in hospital revealed 
low total cholesterol (27 mg/dL) with a very low level 
of HDL-cholesterol (3 mg/dL), apolipoprotein Al 
below detection levels, and a raised triglyceride level 
(231 mg/dL), a characteristic pattern which has been 
observed in malaria patients before.‘-3 Our patient 
received 10 mg/kg per day quinine three times daily 
orally and was clinically and parasitologically cured on 
day 7, with no signs of recrudescence on day 28. Whereas 
hemolysis parameters returned to normal, splenomegaly, 
thrombocytopenia and the abnormal plasma lipid 
pattern persisted at about the same level. When giving 
his medical history, our patient had stated that he under- 
went tonsillectomy early in childhood in connection 
with a rare disease that previously attending physicians 
had suggested before. This led us to suspect Tangier 
disease. The diagnosis was confirmed by demonstration 
by Schmitz and co-workers4 of two novel mutations, 
denoted C2665del and C4457T, of the ABCAl gene, 
coding for the ATP-binding cassette transporter 1. Its 
dysfunction due to various mutations had been recently 
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identified as the cause of not only Tangier disease5-7 but 
also another familial high-density lipoprotein (HDL) 
deficiency8 syndrome, a more frequently occurring, 
related condition in which HDL deficiency is less 
pronounced. 
Tangier disease is a rare autosomal recessive 
disorder of lipid metabolism. Failure to convert 
cholesterol to HDL and to expel it from the cell leads to 
low levels of serum cholesterol and very low HDL and 
apolipoprotein A levels. Owing to storage of cholesterol 
esters in the reticuloendothelial system (RES), hyper- 
trophy and orange-yellow discoloration of the pharyn- 
geal tonsils and mild to moderate (hepato) splenomegaly 
are common, as is thrombocytopenia. Premature 
coronary artery disease (CAD) and a syringomyelia-like 
neurologic syndrome may occur.9 To our knowledge, 
about 60 cases of Tangier disease have been described so 
far worldwide. This is the first report on falciparum 
malaria coinciding with Tangier disease. In both con- 
ditions, different pathomechanisms lead to thrombo- 
cytopenia, splenomegaly (often combined with moderate 
hepatomegaly), and strikingly similar plasma lipid 
changes. In both diseases, thrombocyte function is 
not impaired. In Tangier disease, these features are 
explained by lipid infiltration of bone marrow and RES, 
with hypersplenism possibly contributing to a minor 
extent. Plasma lipid changes represent the primary 
problem leading to secondary organ alterations and 
long-term sequelae. In malaria, the spleen plays an 
essential role in limiting the acute expansion of the 
infection by removing parasitized erythrocytes, and 
thrombocytopenia is mainly due to hypersplenism. 
In non-immune patients, hepatosplenomegaly and 
thrombocytopenia are reversible after treatment of 
malaria, and plasma lipid alterations are transient and 
limited to the parasitemic phase. Temporary HDL 
depletion has been observed in over 90% in some 
studies. A decrease in HDL-C levels as part of the acute- 
phase reaction, diminished hepatic synthesis due to 
affliction of the liver, and direct and parasite-lipo- 
protein interactions, have been suggested as possible 
reasons. Although there is little immediate clinical 
relevance of this phenomenon, it has been suggested as 
an adjuvant diagnostic tool by some authors.‘-” Co- 
morbidity did not influence the course of disease in our 
patient, but clinical aggravation of malaria appears to be 
possible in Tangier disease patients, particularly if the 
immediate diagnosis of falciparum malaria is delayed 
for some reason. In any case, regression of spleen 
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size and normalization of platelet count and plasma 
lipid pattern cannot be used as secondary markers for 
recovery from malaria once co-morbidity with Tangier 
disease exists. 
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